Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? - Wikidata - awgldk - TriplyDB

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

http://www.wikidata.org/entity/Q28077776

about

Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3.ANGPTL3 serum concentration and rare genetic variants in Finnish population.Inulin Improves Postprandial Hypertriglyceridemia by Modulating Gene Expression in the Small Intestine.

P2860

Q45324907-1174D7F6-7B6E-41EB-85C9-96EBCCD573A8 Q47708524-1B477D6C-5998-4229-90DE-694CB4303EAE Q55099469-D987DD4B-758A-43C5-9206-00B01DEDED10

P2860

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

http://www.wikidata.org/entity/Q28077776

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@ast

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@en

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@nl

type

label

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@ast

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@en

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@nl

prefLabel

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@ast

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@en

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@nl

P1433

Q28077776-158D9736-F6B5-41B0-A2C2-C1D0ADCB4B92

P1476

Q28077776-184F4F82-1C65-4395-A199-37CD4B0BB495

P2093

Q28077776-27EF9474-C602-4C98-831F-EC1441BC72DF

P275

Q28077776-96516524-FF57-455C-8B9D-6766C2871BFD

P2860

Q28077776-004CE89F-448A-4BB3-B056-472DF57A8B8D

Q28077776-023BF8DF-9A03-4582-AFF9-93160F8B97F2

Q28077776-055F8E50-564F-4FD6-BD72-D54DB3F562F7

Q28077776-10598B13-CFBF-48DB-A3AF-8B62B5CA8F70

Q28077776-166D681D-9CE1-4071-AF25-5FDB2D810EB4

Q28077776-20A9BD99-62B5-4DB1-841D-8031393169BB

Q28077776-21645E5B-025F-4E04-8B3A-B9B56650FDCE

Q28077776-21D386D9-1847-4ACC-B497-EDF7062AD01B

Q28077776-230E4334-C537-4A42-8B1A-277AE8620AB1

Q28077776-25719F9C-25BE-4B21-8FFB-CF6C0412A458

P2888

Q28077776-259B5D19-7AE0-43EC-A452-C5A7C8C95E52

P304

Q28077776-593A90C2-FAEA-451D-AFAD-0AC77625ECC8

P31

Q28077776-33BA616C-F2C1-4072-A829-F53AA5752D2B

Q28077776-D53BE3FE-AD4F-43AA-8A51-7B79CDA0653B

P3181

Q28077776-C429C740-5CC3-474D-A2E8-A184BB997884

P356

Q28077776-18D6B095-1DD4-46C4-B6D8-A78741ED27EE

P407

Q28077776-529EDEE2-3210-4179-A1EC-AF93CA72D9BC

P433

Q28077776-8515E8C6-2A6C-4117-BE3F-37C401D5D619

P478

Q28077776-9BD97475-B54D-42B3-BA65-60E000E5A347

P50

Q28077776-8D6968AB-91B3-4806-9541-139C51DE54D2

P5008

Q28077776-4ADAF108-8129-4A23-B49E-90E6EAE9C985

P577

Q28077776-38732532-5F82-4591-B0D7-A72E9F10B1B6

Q28077776-E44BC5EE-6D6A-4B74-B84D-E537A5D71F46

P6179

Q28077776-E289E823-F1B1-456B-8815-9CE301503FBC

P698

Q28077776-B77CC3A9-C6E4-4DF7-892D-A05CE3356223

P921

Q28077776-6B6250BE-362F-4069-8A11-329B1DA684A7

Q28077776-9DD33B67-52A0-4CDF-B498-5E0E3EC21294

Q28077776-B20169B2-2096-4742-8340-129CAE614920

Q28077776-B2D22297-8CD9-4719-945F-F1A563CC97BA

Q28077776-D85BEE4C-DD34-49DC-8CF3-2718D4E73F7E

P932

Q28077776-612BB2FC-B781-4A25-8162-4C88B5054ED4

P3181

P356

S11883-016-0614-1

P1433

Current Atherosclerosis Reports

P1476

Why Is Apolipoprotein CIII Eme ...... den of Cardiovascular Disease?

@en

P2093

Marja-Riitta Taskinen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis

The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia

Structure and dynamics of human apolipoprotein CIII

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Linkage of human apolipoproteins A-I and C-III genes

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis

The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR

P2888

s11883-016-0614-1

P304

59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3229831

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11883-016-0614-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047894941

http://www.w3.org/2001/XMLSchema#string

P698

27613744

http://www.w3.org/2001/XMLSchema#string

P921

lipid metabolism disorder

cardiovascular disease

P932

5018018

http://www.w3.org/2001/XMLSchema#string